The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Sun, Yi Yuan ^a   Li, Ming ^a   Li, Yue Yue ^a   Li, Li Xiang ^a   Zhai, Wen Zhe ^a   Wang, Peng ^a   Yang, Xiao Xiao ^a   Gu, Xiang ^a   Song, Li Jin ^a   Li, Zhen ^a   Zuo, Xiu Li ^a   Li, Yan Qing ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ADULT; CLINICAL TRIAL; CLOSTRIDIUM BUTYRICUM; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMAN; IRRITABLE COLON; MALE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CLOSTRIDIUM BUTYRICUM; DIARRHEA; DOUBLE-BLIND METHOD; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PLACEBOS; PROBIOTICS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 85042075717     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-21241-z     Document Type: Article

References (40)

1. Longstreth, G. F. et al. Functional bowel disorders. Gastroenterology 130, 1480-1491, https://doi. org/10. 1053/j. gastro. 2005. 11. 061 (2006).
2. Guglielmetti, S., Mora, D., Gschwender, M. & Popp, K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. Alimentary pharmacology & therapeutics 33, 1123-1132, https://doi. org/10. 1111/j. 1365-2036. 2011. 04633. x (2011).
3. Ki Cha, B. et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Journal of clinical gastroenterology 46, 220-227, https://doi. org/10. 1097/MCG. 0b013e31823712b1 (2012).
4. American College of Gastroenterology Task Force on Irritable Bowel, S. et al. An evidence-based position statement on the management of irritable bowel syndrome. The American journal of gastroenterology 104(Suppl 1), S1-35, https://doi. org/10. 1038/ ajg. 2008. 122 (2009).
5. Gwee, K. A. et al. Asian consensus on irritable bowel syndrome. Journal of gastroenterology and hepatology 25, 1189-1205, https:// doi. org/10. 1111/j. 1440-1746. 2010. 06353. x (2010).
6. Ringel, Y. & Carroll, I. M. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointestinal endoscopy clinics of North America 19, 141-150, https://doi. org/10. 1016/j. giec. 2008. 12. 004 (2009). vii.
7. Jeffery, I. B. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61, 997-1006, https://doi. org/10. 1136/gutjnl-2011-301501 (2012).
8. Carroll, I. M. et al. Molecular analysis of the luminal-and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. American journal of physiology. Gastrointestinal and liver physiology 301, G799-807, https://doi. org/10. 1152/ajpgi. 00154. 2011 (2011).
9. Hod, K. & Ringel, Y. Probiotics in functional bowel disorders. Best practice & research. Clinical gastroenterology 30, 89-97, https:// doi. org/10. 1016/j. bpg. 2016. 01. 003 (2016).
10. Zhang, Y. et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC gastroenterology 16, 62, https://doi. org/10. 1186/s12876-016-0470-z (2016).
11. Sisson, G., Ayis, S., Sherwood, R. A. & Bjarnason, I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome-a 12 week double-blind study. Alimentary pharmacology & therapeutics 40, 51-62, https://doi. org/10. 1111/apt. 12787 (2014).
12. Spiller, R. et al. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European gastroenterology journal 4, 353-362, https://doi. org/10. 1177/2050640615602571 (2016).
13. Zeng, J. et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary pharmacology & therapeutics 28, 994-1002, https://doi. org/10. 1111/j. 1365-2036. 2008. 03818. x (2008).
14. Rousseaux, C. et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature medicine 13, 35-37, https://doi. org/10. 1038/nm1521 (2007).
15. Wang, B. et al. Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 4078-4088, https://doi. org/10. 1096/fj. 09-153841 (2010).
16. O'Mahony, L. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551, https://doi. org/10. 1053/j. gastro. 2004. 11. 050 (2005).
17. Mo, S. et al. Genome sequencing of Clostridium butyricum DKU-01, isolated from infant feces. Gut pathogens 7, 8, https://doi. org/10. 1186/s13099-015-0055-3 (2015).
18. Yasueda, A. et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. Surgery today 46, 939-949, https://doi. org/10. 1007/s00595-015-1261-9 (2016).
19. Seki, H. et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatrics international: official journal of the Japan Pediatric Society 45, 86-90 (2003).
20. Francis, C. Y., Morris, J. & Whorwell, P. J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Alimentary pharmacology & therapeutics 11, 395-402 (1997).
21. Patrick, D. L., Drossman, D. A., Frederick, I. O., DiCesare, J. & Puder, K. L. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Digestive diseases and sciences 43, 400-411 (1998).
22. Lewis, S. J. & Heaton, K. W. Stool form scale as a useful guide to intestinal transit time. Scandinavian journal of gastroenterology 32, 920-924, https://doi. org/10. 3109/00365529709011203 (1997).
23. Wang, A. H. et al. Human colorectal mucosal microbiota correlates with its host niche physiology revealed by endomicroscopy. Scientific reports 6, 21952, https://doi. org/10. 1038/srep21952 (2016).
24. Niv, E., Naftali, T., Hallak, R. & Vaisman, N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clinical nutrition 24, 925-931, https://doi. org/10. 1016/j. clnu. 2005. 06. 001 (2005).
25. Kashiwagi, I. et al. Smad2 and Smad3 Inversely Regulate TGF-beta Autoinduction in Clostridium butyricum-Activated Dendritic Cells. Immunity 43, 65-79, https://doi. org/10. 1016/j. immuni. 2015. 06. 010 (2015).
26. Hayashi, A. et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell host & microbe 13, 711-722, https://doi. org/10. 1016/j. chom. 2013. 05. 013 (2013).
27. Tana, C. et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society 22, 512-519, e114-515, https://doi. org/10. 1111/j. 1365-2982. 2009. 01427. x (2010).
28. Treem, W. R., Ahsan, N., Kastoff, G. & Hyams, J. S. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. Journal of pediatric gastroenterology and nutrition 23, 280-286 (1996).
29. Peng, L., Li, Z. R., Green, R. S., Holzman, I. R. & Lin, J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. The Journal of nutrition 139, 1619-1625, https://doi. org/10. 3945/jn. 109. 104638 (2009).
30. Guilloteau, P. et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutrition research reviews 23, 366-384, https://doi. org/10. 1017/S0954422410000247 (2010).
31. Meijer, K., de Vos, P. & Priebe, M. G. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Current opinion in clinical nutrition and metabolic care 13, 715-721, https://doi. org/10. 1097/MCO. 0b013e32833eebe5 (2010).
32. Leonel, A. J. & Alvarez-Leite, J. I. Butyrate: implications for intestinal function. Current opinion in clinical nutrition and metabolic care 15, 474-479, https://doi. org/10. 1097/MCO. 0b013e32835665fa (2012).
33. Bourdu, S. et al. Rectal Instillation of Butyrate Provides a Novel Clinically Relevant Model of Noninflammatory Colonic Hypersensitivity in Rats. Gastroenterology 128, 1996-2008, https://doi. org/10. 1053/j. gastro. 2005. 03. 082 (2005).
34. Xu, D., Wu, X., Grabauskas, G. & Owyang, C. Butyrate-induced colonic hypersensitivity is mediated by mitogen-activated protein kinase activation in rat dorsal root ganglia. Gut 62, 1466-1474, https://doi. org/10. 1136/gutjnl-2012-302260 (2013).
35. Gupta, R. S. & Gao, B. Phylogenomic analyses of clostridia and identification of novel protein signatures that are specific to the genus Clostridium sensu stricto (cluster I). International journal of systematic and evolutionary microbiology 59, 285-294, https://doi. org/10. 1099/ijs. 0. 001792-0 (2009).
36. Rajilic-Stojanovic, M. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792-1801, https://doi. org/10. 1053/j. gastro. 2011. 07. 043 (2011).
37. Distrutti, E., Monaldi, L., Ricci, P. & Fiorucci, S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World journal of gastroenterology 22, 2219-2241, https://doi. org/10. 3748/wjg. v22. i7. 2219 (2016).
38. Ponnusamy, K., Choi, J. N., Kim, J., Lee, S. Y. & Lee, C. H. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. Journal of medical microbiology 60, 817-827, https://doi. org/10. 1099/jmm. 0. 028126-0 (2011).
39. Sikander, A., Rana, S. V. & Prasad, K. K. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clinica chimica acta; international journal of clinical chemistry 403, 47-55, https://doi. org/10. 1016/j. cca. 2009. 01. 028 (2009).
40. Atkinson, W., Lockhart, S., Whorwell, P. J., Keevil, B. & Houghton, L. A. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130, 34-43, https://doi. org/10. 1053/j. gastro. 2005. 09. 031 (2006).